Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Novel blood test helps doctors to manage patients with shortness of breath

01.09.2003


ESC Congress 2003: Hot Line I - Medical Treatment & Heart Failure



We have shown that a simple blood test measuring B-type natriuretic peptide (BNP), a marker of heart failure, greatly helps doctors to manage patients presenting with shortness of breath to the emergency department. Used in conjunction with other clinical information, rapid measurement of BNP reduced hospitalisations, reduced need for intensive care, reduced total treatment time and significantly reduced total treatment cost by 25%.

Shortness of breath is the key symptom of numerous disorders. Cardiac and pulmonary disease are very common and the most important. Unfortunately, the rapid and accurate differentiation of cardiac disease (heart failure) from other causes of shortness of breath remains a clinical challenge, especially in the emergency department.


Heart failure is a major public health problem. Currently, there are more than 15 million patients with heart failure in North America and Europe, with nearly 1.5 million new cases every year. Heart failure is the most frequent cause of hospitalisation in patients more than 65 years of age and these hospitalisations contribute significantly to the enormous cost of the disease. The total direct cost of care for heart failure exceed $38 billion in the United States per year. Therefore, cost-effective management is of paramount importance.

BNP levels have been found to be significantly higher in patients with heart failure as compared with patients whose shortness of breath is due to other causes. Finding a low BNP level in a patient with shortness of breath renders heart failure unlikely and helps the doctor to focus on alternative causes. In contrast, a high BNP level strongly argues for heart failure being the cause. Accordingly, heart failure medication can be initiated immediately. Our study is the first in the world to demonstrate that in fact doctors can do a better job with the rapid measurement of this novel cardiac marker.

The BASEL (B-Type Natriuretic Peptide for Acute Shortness of Breath Evaluation) study was carried out in the emergency department of our inner city University hospital in Basel, Switzerland. It was supported by research grants from the Swiss National Science Foundation, the Swiss Heart Foundation, the Novartis Foundation, the Krokus Foundation, and the University of Basel. We looked at 452 patients who presented with shortness of breath. The usual diagnostic work-up included patient history, physical examination, ECG, chest X-ray and routine blood tests in all patients. In addition, BNP levels were determined in 225 patients (BNP group). The patients did not know whether their work-up included BNP testing or not. Our results show that the use of BNP levels significantly reduced the need for hospital admission (75% versus 85%) or intensive care (15% versus 24%). Total treatment time was 10.5 days in the BNP group as compared with 13.7 days in the clinical group, a significant reduction of 23%. Total cost of treatment was $5,410 in the BNP group as compared with $7,264 in the clinical group, a significant reduction of 26%. Extrapolating this finding to the cost of hospitalisations for heart failure in the United States in 2000 of $30 billion, the use of this simple blood test may save up to $7 billion each year in the United States alone.

Additional studies have been launched to test whether BNP proves also helpful for the evaluation of patients with shortness of breath presenting in doctors office.

Christian Müller, M.D.
University Hospital, Basel
Switzerland

IMPORTANT: This press release accompanies both a presentation and an ESC press conference given at the ESC Congress 2003. Written by the investigator himself/herself, this press release does not necessarily reflect the opinion of the European Society of Cardiology

Camilla Dormer | alfa
Further information:
http://www.escardio.org/vpo

More articles from Health and Medicine:

nachricht Laser activated gold pyramids could deliver drugs, DNA into cells without harm
24.03.2017 | Harvard John A. Paulson School of Engineering and Applied Sciences

nachricht What does congenital Zika syndrome look like?
24.03.2017 | University of California - San Diego

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

Im Focus: Researchers Imitate Molecular Crowding in Cells

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

Argon is not the 'dope' for metallic hydrogen

24.03.2017 | Materials Sciences

Astronomers find unexpected, dust-obscured star formation in distant galaxy

24.03.2017 | Physics and Astronomy

Gravitational wave kicks monster black hole out of galactic core

24.03.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>